CLPX

Across TCGA pan-cancer cohorts, CLPX mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLPX data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLPX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLPX expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and CCRCC are the cancer types where CLPX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	1.000	0.450	.004	17	view →
CCRCC	DFS	Median	II,III,IV	0.471	0.773	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLPX–LUAD (OS)

Open the LUAD breakdown →